Clinically relevant stratification of DLBCL is largely non-existent and a classification such as a combination of CD10, BCL6, and IRF4/MUM1 expression, so-called “Hans classifier” was proposed to be useful in predicting long or short term survival (Hans et al., 2004). The gene discussed is IRF4; the disease is diffuse large B-cell lymphoma.